· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2023 / N 4 Митохондриальный метаболизм как важная терапевтическая мишень в терапии пациента с сердечной недостаточностью В.Н. Шишкова Список литературы/References 1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 2022;24(1):4-131. DOI: 10.1002/ejhf.2333 2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1789-1858. DOI: 10.1016/S0140-6736(18)32279-7 3. Writing Group Members; Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38-e360. DOI: 10.1161/CIR.0000000000000350 4. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña IL, Trogdon JG; American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation. Heart Failure. 2013;6(3):606-619. DOI: 10.1161/HHF.0b013e318291329a 5. Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. European Journal of Heart Failure. 2019;21(11):1306-1325. DOI: 10.1002/ejhf.1594 6. Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C, Kadam UT, Kwok CS, Clark AB, Murchie P, Buchan I, Hannaford PC, Myint PK. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. European Journal of Heart Failure. 2017;19(9):1095-1104. DOI: 10.1002/ejhf.822 7. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research. 2023;118(17):3272-3287. DOI: 10.1093/cvr/cvac013 8. Neubauer S. The failing heart – an engine out of fuel. The New England Journal of Medicine. 2007;356(11):1140-1151. DOI: 10.1056/NEJMra063052 9. Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circulation Research. 2013;113(6):709-724. DOI: 10.1161/CIRCRESAHA.113.300376 10. Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Tamaki Y, Iwanaga Y, Narazaki M, Matsuda T, Soga T, Kita T, Kimura T, Shioi T. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circulation. Heart Failure. 2010;3(3):420-430. DOI: 10.1161/CIRCHEARTFAILURE.109.888479 11. Stride N, Larsen S, Hey-Mogensen M, Sander K, Lund JT, Gustafsson F, Køber L, Dela F. Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction. European Journal Heart Failure. 2013;15(2):150-157. DOI: 10.1161/CIRCHEARTFAILURE.109.888479 12. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996;94(11):2837-2842. DOI: 10.1161/01.cir.94.11.2837 13. Mazer CD, Stanley WC, Hickey RF, Neese RA, Cason BA, Demas KA, Wisneski JA, Gertz EW. Myocardial metabolism during hypoxia: maintained lactate oxidation during increased glycolysis. Metabolism. 1990;39(9):913-918. DOI: 10.1016/0026-0495(90)90300-2 14. Doenst T, Pytel G, Schrepper A, Amorim P, Färber G, Shingu Y, Mohr FW, Schwarzer M. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovascular Research. 2010;86(3):461-470. DOI: 10.1093/cvr/cvp414 15. Nguyen TD, Schulze PC. Lipid in the midst of metabolic remodeling – therapeutic implications for the failing heart. Advanced Drug Delivery Reviews. 2020;159:120-132. DOI: 10.1016/j.addr.2020.08.004 16. Murray AJ, Cole MA, Lygate CA, Lygate CA, Carr CA, Stuckey DJ, Little SE, Neubauer S, Clarke K. Increased mitochondrial uncoupling proteins, respiratory uncoupling and decreased efficiency in the chronically infarcted rat heart. Journal of Molecular and Cellular Cardiology. 2008;44(4):694-700. DOI: 10.1016/j.yjmcc.2008.01.008 17. Garnier A, Fortin D, Delomenie C, Momken I, Veksler V, Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. Journal of Physiology. 2003;551(Pt. 2):491-501. DOI: 10.1113/jphysiol.2003.045104 18. Buchwald A, Till H, Unterberg C, Oberschmidt R, Figulla HR, Wiegand V. Alterations of the mitochondrial respiratory chain in human dilated cardiomyopathy. European Heart Journal. 1990;11:509-516. DOI: 10.1093/oxfordjournals.eurheartj.a059743 19. Girerd N. Is the correction of micronutrient deficiencies the next step in heart failure management? Journal of Internal Medicine. 2022;291(6):710-712. DOI: 10.1111/joim.13455 20. Bomer N, Pavez-Giani M, Grote Beverborg N, Cleland JGF, van Veldhuisen DJ, van der Meer Pl. Micronutrient deficiencies in heart failure: mitochondrial dysfunction as a common pathophysiological mechanism? Journal of Internal Medicine. 2022;291(6):713-731. DOI: 10.1111/joim.13456 21. Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC Jr, Suthammarak W, Gong G, Sedensky MM, Morgan PG, Wang W, Tian R. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metabolism. 2013;18(2):239-250. DOI: 10.1016/j.cmet.2013.07.00 22. Chaanine AH, Joyce LD, Stulak JM, Maltais S, Joyce DL, Dearani JA, Klaus K, Nair KS, Hajjar RJ, Redfield MM. Mitochondrial morphology, dynamics, and function in human pressure overload or ischemic heart disease with preserved or reduced ejection fraction. Circulation. Heart Failure. 2019;12(2):e005131. DOI: 10.1161/CIRCHEARTFAILURE.118.005131 23. Karamanlidis G, Nascimben L, Couper GS, Shekar PS, del Monte F, Tian R. Defective DNA replication impairs mitochondrial biogenesis in human failing hearts. Circulation Research. 2010;106(9):1541-1548. DOI: 10.1161/CIRCRESAHA.109.212753 24. Pisano A, Cerbelli B, Perli E, Pelullo M, Bargelli V, Preziuso C, Mancini M, He L, Bates MG, Lucena JR, Della Monica PL, Familiari G, Petrozza V, Nediani C, Taylor RW, d’Amati G, Giordano C. Impaired mitochondrial biogenesis is a common feature to myocardial hypertrophy and end-stage is chemic heart failure. Cardiovascular Pathology. 2016;25(2):103-112. DOI: 10.1016/j.carpath.2015.09.009 25. Dorn GW 2nd, Vega RB, Kelly DP. Mitochondrial biogenesis and dynamics in the developing and diseased heart. Genes & Development. 2015;29(19):1981-1991. DOI: 10.1101/gad.269894.115 26. Bugger H, Schwarzer M, Chen D, Schrepper A, Amorim PA, Schoepe M, Nguyen TD, Mohr FW, Khalimonchuk O, Weimer BC, Doenst T. Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovascular Research. 2010;85(2):376-384. DOI: 10.1093/cvr/cvp344 27. Song M, Dorn GW 2nd. Mitoconfusion: noncanonical functioning of dynamism factors in static mitochondria of the heart. Cell Metabolism. 2015;21(2):195-205. DOI: 10.1016/j.cmet.2014.12.019 28. Chen L, Gong Q, Stice JP, Knowlton AA. Mitochondrial OPA1, apoptosis, and heart failure. Cardiovascular Research. 2009;84:91-99. DOI: 10.1093/cvr/cvp181 29. Sabbah HN. Targeting the mitochondria in heart failure: a translational perspective. JACC. Basic to Translational Science. 2020;5(1):88-106. DOI: 10.1016/j.jacbts.2019.07.009 30. Chen L, Liu T, Tran A, Lu X, Tomilov AA, Davies V, Cortopassi G, Chiamvimonvat N, Bers DM, Votruba M, Knowlton AA. OPA1 mutation and late-onset cardiomyopathy: mitochondrial dysfunction and mtDNA instability. Journal of the American Heart Association. 2012;1:e003012. DOI: 10.1161/JAHA.112.003012 31. Piquereau J, Caffin F, Novotova M, Prola A, Garnier A, Mateo P, Fortin D, Huynh le H, Nicolas V, Alavi MV, Brenner C, Ventura-Clapier R, Veksler V, Joubert F. Down-regulation of OPA1 alters mouse mitochondrial morphology, PTP function, and cardiac adaptation to pressure overload. Cardiovascular Research. 2012;94(3):408-417. DOI: 10.1093/cvr/cvs117 32. Шишкова В.Н. Коморбидность и полипрогмазия: фокус на цитопротекцию. Consilium Medicum. 2016;18(12):65-71. [Shishkova VN. Comorbidity and polyprogmasia: focus on cytoprotection. Consilium Medicum. 2016;18(12):65-71. (In Russ.).] 33. Шишкова В.Н., Мартынов А.И. Современные возможности терапии метаболической кардиопиопатии и сердечной недостаточности. Терапия. 2020;6:139-149. [Shishkova VN, Martynov AI. Modern opportunities of therapy for metabolic cardiopathia and heart failure. Therapy. 2020;6:139-149. (In Russ.).] DOI: 10.18565/therapy.2020.6.139-1495 34. Liepinsh E, Skapare E, Kuka J, Makrecka M, Cirule H, Vavers E, Sevostjanovs E, Grinberga S, Pugovics O, Dambrova M. Activated peroxisomal fatty acid metabolism improves cardiac recovery in ischemia‐reperfusion. Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie. 2013;386(6):541-550. DOI: 10.1007/s00210‐013‐0849‐0 35. Шафоростова Е.А., Гуреев А.П., Виткалова И.Ю., Попов В.Н. Влияние истощения L-карнитина при длительной терапии мельдонием на митохондриальный баланс в мозге мыши. Биомедицинская химия. 2021;67(1):74-80. [Shaforostova EA, Gureyev AP, Vitkalova IYu, Popov VN. The effect of L-carnitine depletion induced by long-term therapy of mice with meldonium on brain mitochondrial balance. Biomeditsinskaya Khimiya. 2021;67(1):74-80. (In Russ.).] DOI: 10.18097/PBMC20216701074 36. Bergeron R, Ren JM, Cadman KS, Moore IK, Perret P, Pypaert M, Young LH, Semenkovich CF, Shulman GI. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. American Journal of Physiology. Endocrinology and Metabolism. 2001;281(6):E1340-E1346. DOI: 10.1152/ajpendo.2001.281.6.E1340 37. Gureev AP, Shaforostova EA, Vitkalova IYu, Sadovnikova IS, Kalinina YI, Cherednichenko VR, Reznikova KA, Valuyskikh VV, Popov VN. Long-term mildronate treatment increased Proteobacteria level in gut microbiome, and caused behavioral deviations and transcriptome change in liver, heart and brain of healthy mice. Toxicology and Applied Pharmacology. 2020;398:115031. DOI: 10.1016/j.taap.2020.115031 38. Tomasello MF, Guarino F, Reina S, Messina A, De Pinto V. The Voltage-Dependent Anion selective Channel 1 (VDAC1) topography in the mitochondrial outer membrane as detected in intact cell. PLoS One. 2013;8(12):e81522. DOI: 10.1371/journal.pone.0081522 39. Picard M, Shirihai OS, Gentil BJ, Burelle Y. Mitochondrial morphology transitions and functions: implications for retrograde signaling? The American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2013;304(6):R393-R406. DOI: 10.1152/ajpregu.00584.2012 40. Стаценко М.Е., Туркина С.В., Лопушкова Ю.Е., Косивцова М.А. Пациент с хронической сердечной недостаточностью и хронической обструктивной болезнью легких: новые возможности лечения. Медицинский совет. 2022;16(6):13-22. [Statsenko ME, Turkina SV, Lopushkova YuE, Kosivtsova MA. New treatment options for a patient with chronic heart failure and chronic obstructive pulmonary disease. Medical Council. 2022;16(6):13-22. (In Russ.).] DOI: 10.21518/2079-701X-2022-16-6-13-22 41. Vilskersts R, Kigitovica D, Korzh S, Videja M, Vilks K, Cirule H, Skride A, Makrecka-Kuka M, Liepinsh E, Dambrova M. Protective effects of meldonium in experimental models of cardiovascular complications with a potential application in COVID‐19. International Journal of Molecular Sciences. 2021;23(1):45. DOI: 10.3390/ijms23010045 42. Верткин А.Л., Шишкова В.Н., Сычева А.С., Кебина А.Л., Носова А.В., Урянская К.А., Газикова Х.М., Завьялов Г.В. Возможности метаболической поддержки при коронавирусной инфекции. Терапия. 2020;7:146-155. [Vertkin AL, Shishkova VN, Sycheva AS, Kebina AL, Nosova AV, Uryanskaya KA, Gazikova KhM, Zavyalov GV. Options of metabolic support in case of coronavirus infection. Therapy. 2020;7:146-155. (In Russ.).] DOI: 10.18565/therapy.2020.7.146-155 43. Шишкова В.Н. Мартынов А.И. Инсулинорезистентность: фокус на патогенез кардиомиопатии. Consilium Medicum. 2020;22(10):52-54. [Shishkova VN, Martynov AI. Insulin resistance: focus on the pathogenesis of cardiomyopathy. Consilium Medicum. 2020;22(10):52-54. (In Russ.).] DOI: 10.26442/20751753.2020.10.200341 44. Visokinskas A, Kalvinsh I, Knasiene J, Lesauskaite V, Macijauskiene J, Jankauskiene L. Use of mildronate in geriatric patients with congestive heart failure. Journal of the Indian Academy of Geriatrics. 2005;1(3):110-113. 45. Jaudzems K, Kuka J, Gutsaits A, Zinovjevs K, Kalvinsh I, Liepinsh E, Liepinsh E, Dambrova M. Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism. Journal of Enzyme Inhibition and Medicinal Chemistry. 2009;24(6):1269-1275. DOI: 10.3109/14756360902829527 46. Skarda I, Klincare D, Dzerve V, Vitols A, Kukulis I, Kalnins U, Karpov R, Koshelskaya O, Semyonova S, Matveja L, Kalvins I. Modulation of myocardial energy metabolism with mildronate – an effective approach in the treatment of chronic heart failure. Proceedings of the Latvian Academy of Sciences. 2001;55(2-3):73-79. 47. Стаценко М.Е., Туркина С.В., Беленкова С.В., Полетаева Л.В., Дудченко Г.П. Влияние милдроната в составе комбинированной терапии хронической сердечной недостаточности у больных сахарным диабетом типа 2 на углеводный, липидный обмен и показатели оксидативного стресса. Российский кардиологический журнал. 2010;2(82):45-51. [Statsenko ME, Turkina SV, Belenkova SV, Poletayeva LV, Dudchenko GP. Effects of mildronate, as a part of combined heart failure therapy, on carbohydrate and lipid metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus. Russian Journal of Cardiology. 2010;2(82):45-51. (In Russ.).] DOI: 10.15829/1560-4071-2010-2-45-51 48. Галявич А.С., Галеева З.М., Балеева Л.В. Эффективность и переносимость милдроната при лечении пациентов с хронической сердечной недостаточностью. Российский кардиологический журнал. 2005;5(55):1-4. [ Galyavich AS, Galeyeva ZM, Baleyeva LV. Efficacy and tolerability of mildronate in treatment of patients with chronic heart failure. Russian Journal of Cardiology. 2005;5(55):1-4. (In Russ.).] 49. Семенкова Г.Г., Кокорева Л.В. Сравнительная эффективность лечения больных хронической сердечной недостаточностью с применением миокардиальных цитопротекторов. Российский кардиологический журнал. 2007;12(2):77-82. [Semenkova GG, Kokoreva LV. Comparative effectiveness of treatment of myocardial cytoprotectors in chronic heart failure treatment. Russian Journal of Cardiology. 2007;12(2):77-82. (In Russ.).] 50. Соколов А.А., Карпов Р.С., Тепляков А.Т., Кошельская О.А., Урбане Д., Кальвиньш И., Калниньш У., Витолс А.И., Врубаевский А.В., Дзерве В., Клинцаре А., Матвея А.И., Скарда И. Клиническая эффективность и безопасность милдроната при лечении хронической сердечной недостаточности у больных ишемической болезнью сердца. Кардиология. 2000;6:69-74. [Sokolov AA, Karpov RS, Teplyakov AT, Koshelskaya OA, Urbane D, Kalvinsh I, Kalninsh U, Vitols AI, Vrubayevskiy AV, Dzerve V, Klintsare A, Matvey AI, Skarda I. Clinical efficacy and safety of mildronate in treatment of chronic heart failure in patients with coronary heart disease. Kardiologiia. 2000;6:69-74. (In Russ.).] 51. Недошивин А.О., Петрова Н.Н., Кутузова А.Е., Перепеч Н.Б. Качество жизни больных с хронической сердечной недостаточностью. Эффект лечения милдронатом. Терапевтический архив. 1999;71(8):10-12. [Nedoshivin AO, Petrova NN, Kutuzova AE, Perepech NB. Quality of life in patients with chronic heart failure. The effect of mildronate treatment. Therapeutic Archive. 1999;71(8):10-12. (In Russ.).]    [ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]